Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ACAB) is a clinical-stage biopharmaceutical company specializing in multi-specific antibody engineering that became publicly listed through a SPAC business combination. The blank-check vehicle, Atlantic Coastal Acquisition Corp. II, completed its IPO in 2022 targeting the healthcare and life sciences sector. Abpro filed an 8-K with the Securities and Exchange Commission on December 12, 2023, disclosing a material corporate event under the combined public entity. The company's proprietary antibody platform is designed to advance therapeutic candidates in oncology and other serious disease areas. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal analytics on ACAB and the broader SPAC market.